NURECA

₹291.35 +13.95 (5.03%)

28 Dec, 2024 01:36

SIP TrendupStart SIP in NURECA

Start SIP

Performance

  • Low
  • ₹278
  • High
  • ₹296
  • 52 Week Low
  • ₹240
  • 52 Week High
  • ₹444
  • Open Price₹279
  • Previous Close₹277
  • Volume18,994

Investment Returns

  • Over 1 Month + 4.18%
  • Over 3 Month -19.87%
  • Over 6 Month + 4.93%
  • Over 1 Year -36.14%
SIP Lightning

Smart Investing Starts Here Start SIP with Nureca for Steady Growth!

Invest Now

Nureca Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -104
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 291
  • P/B Ratio
  • 1.5
  • Average True Range
  • 10.04
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.58
  • RSI
  • 55.57
  • MFI
  • 48.81

Nureca Financials

Nureca Technicals

EMA & SMA

Current Price
₹291.35
+ 13.95 (5.03%)
pointer
  • stock-down_img
  • Bullish Moving Average 13
  • stock-up_img
  • Bearish Moving Average 3
  • 20 Day
  • ₹284.56
  • 50 Day
  • ₹289.62
  • 100 Day
  • ₹294.33
  • 200 Day
  • ₹306.27

Resistance and Support

288.37 Pivot Speed
  • R3 317.83
  • R2 307.02
  • R1 299.18
  • S1 280.53
  • S2 269.72
  • S3 261.88

What's your outlook on Nureca?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nureca has an operating revenue of Rs. 90.80 Cr. on a trailing 12-month basis. An annual revenue de-growth of -14% needs improvement, Pre-tax margin of -3% needs improvement, ROE of -0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 13 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 21 indicates it belongs to a strong industry group of Medical-Products and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nureca Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results
2024-08-05 Quarterly Results
2024-05-15 Audited Results
2024-02-07 Quarterly Results
2023-11-04 Quarterly Results
Date Purpose Remarks
2022-02-25 INTERIM Rs.3.00 per share(30%)Interim Dividend

Nureca F&O

Nureca Shareholding Pattern

63.77%
0.69%
32.97%
2.57%

About Nureca

  • NSE Symbol
  • NURECA
  • BSE Symbol
  • 543264
  • Chairman & Managing Director
  • Mr. Saurabh Goyal
  • ISIN
  • INE0DSF01015

Similar Stocks to Nureca

Nureca FAQs

Nureca share price is ₹291 As on 28 December, 2024 | 01:23

The Market Cap of Nureca is ₹291.4 Cr As on 28 December, 2024 | 01:23

The P/E ratio of Nureca is -104 As on 28 December, 2024 | 01:23

The PB ratio of Nureca is 1.5 As on 28 December, 2024 | 01:23

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23